Background-Patients with atrial fibrillation (AF) face significant risks of stroke and heart failure. The objective of this study was to determine whether AF ablation reduces the long-term risk of stroke or heart failure compared with antiarrhythmic drug therapy.
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Since its initial description in the late 1990s, 9 catheter ablation for AF has grown into an effective and important treatment option for many patients. 10, 11 Multiple small-to medium-sized clinical trials have established that AF ablation maintains sinus rhythm more effectively than antiarrhythmic medications as a second-line and possibly a first-line strategy [12] [13] [14] and that this improved rhythm control is associated with improved symptoms and quality of life. 15, 16 Despite these important findings, the potential health benefits of catheter ablation for AF remain less than fully certain, in large part because completed trials of AF ablation have been modest in size, enrolled relatively low-risk patients, and rarely observed patients for Ͼ1 year. Although several studies of patients with preexisting heart failure have shown that AF ablation can improve cardiac structure and function, as well as heart failure symptoms, 17, 18 it has not been established whether AF ablation can reduce the risk of heart failure events in the wider population of patients who undergo the procedure. In addition, although 1 nonrandomized cohort study reported a reduction in stroke risk after AF ablation, 19 and other investigators have reported low stroke rates in patients who discontinue anticoagulation after ablation, 20 the potential impact of AF ablation on stroke risk remains unclear.
To help address these questions, we obtained access to a large national claims database with the objective of comparing medium-term rates of stroke or transient ischemic attack (TIA) and heart failure hospitalization in patients treated with AF ablation, compared with similar patients being treated with antiarrhythmic medications but not ablation.
WHAT IS KNOWN
• Atrial fibrillation (AF) is associated with an increased risk of stroke and other adverse cardiovascular outcomes, such as heart failure. • In selected patients with AF, radiofrequency catheter ablation is more effective than antiarrhythmic drug therapy at maintaining normal sinus rhythm. • Most published data on AF ablation have come from large academic centers with great skill and experience in performing the procedure.
WHAT THE STUDY ADDS
• This study compared outcomes for up to 3 years in patients with AF treated with radiofrequency catheter ablation with those of similar patients (based on propensity matching) treated with antiarrhythmic drugs. • We found a significant difference in the long-term rate of stroke or transient ischemic attack, which was lower in the ablation group than the nonablation group (3.4% versus 5.5% per year), but no significant difference in the rate of hospitalization for heart failure.
Methods
To compare outcomes of patients with AF treated with ablation with those of patients treated with antiarrhythmic medications, we derived 2 separate patient cohorts using claims data. Propensity-matching techniques were then used to select a subset of patients for outcomes analysis that would be as similar as possible to each other.
Data Source
We analyzed data from the US MarketScan Commercial Claims and Encounters Database and Medicare Supplemental Database from Thomson Reuters (New York, NY). 21 The databases are composed of deidentified patient-level records from Ͼ121 million patients since 1995, enrolled in both employer-sponsored and public health insurance plans. They include paid and adjudicated claims for employees, spouses, and dependents, as well as retirees with Medicare supplemental insurance. In particular, they include data from 150 employers and 21 health plans, representing 130 unique carriers, and are nationally representative of Americans with employerprovided health insurance. The MarketScan databases have supported Ͼ425 articles on health research published in major peerreviewed journals since 1990 and are in compliance with the Health Information Portability and Accountability Act of 1996. 21, 22 A protocol describing the study objectives, criteria for patient selection, data elements of interest, and statistical methods was submitted to the New England Institutional Review Board and deemed exempt from review.
Patient Selection and Data Capture
Analyzable patient records were drawn from the MarketScan databases from January 1, 2005, through the first quarter of 2009. To be eligible for inclusion in the analysis, patients in the ablation cohort were required to have an inpatient or outpatient visit with both a recorded diagnosis of AF (International Classification of Diseases, Ninth Revision [ICD-9] code 427.31) and a documented catheter ablation procedure (ICD-9 code 37.34 and/or Current Procedural Terminology code 93651), but with no code designating a pacemaker or implantable cardioverter defibrillator implantation. For the inpatient setting, the ICD-9 codes for AF and catheter ablation were designated as the primary diagnosis and procedure associated with the admission. A record of any cardiac ablation procedure before the first procedure meeting the previously described requirements caused a patient to be excluded from the analysis. The presence of a procedure code for open (surgical) ablation procedure or atrioventricular junction ablation at the same visit also resulted in exclusion. The analytic start time was defined for this cohort as the date of the first catheter ablation procedure meeting the inclusion-exclusion criteria.
A separate cohort of patients with AF treated with antiarrhythmic medications but not ablation was also derived. These patients were also required to have a diagnosis of AF but could not have any record of an ablation procedure either before or after the analytic start time. In addition, they had to have records of at least 2 different antiarrhythmic drug prescriptions after their first recorded AF diagnosis. The first record of the second antiarrhythmic agent was then used as the analytic start time for this cohort.
Both cohorts of patients were required to have 6 months of continuous enrollment in the MarketScan database immediately before their respective start times and 1 year of continuous enrollment in the database immediately afterward. Details of the coding algorithm used to identify patients can be seen in Figure 1A and 1B. Variations in the selection rules between outpatients and inpatients in the ablation cohort are because of the differences in diagnostic and procedural coding for these 2 settings. For example, outpatient visits typically have Current Procedural Terminology codes only for procedures, rather than ICD-9 codes, whereas inpatient visits always have ICD-9 codes for the primary procedure code. In addition, outpatient visits do not designate a principal diagnosis or procedure code, as is done with inpatient visits.
For each patient identified as previously described, claims in the database were used to record their demographics, the presence or absence of selected comorbid conditions, history of medication use for drug categories of interest, history of cardioversions, and use of medical services. Demographics and other general descriptive variables include age, sex, procedure setting (inpatient or outpatient), year of procedure, insurance and location variables, length of primary ablation hospital stay, and length of time in the database. The comorbid conditions of interest include various categories of structural heart disease, hypertension, diabetes, chronic obstructive pulmonary disease, and acute renal failure. Drug categories related to the treatment of AF include rhythm control medications, rate control medications, and warfarin. CHADS2 scores are an indicator of stroke risk, which range from 0 to 6. Congestive heart failure, hypertension, diabetes, and stroke were defined by ICD-9 diagnosis codes; these characteristics, along with age, were used to determine CHADS2 scores.
Study Design
This study used a retrospective matched cohort design, with the matched sample chosen from 3194 catheter ablation patients and 6028 nonablation patients in the MarketScan Research Database from Thomson Reuters who met the predefined inclusion and exclusion criteria.
Propensity scores for receipt of a catheter ablation were calculated for each of the 9222 patients based on a multivariable logistic regression model. A total of 24 characteristics (including demo- graphic, clinical, and resource use variables) hypothesized to be associated with having a catheter ablation were assessed for inclusion in the model as independent variables. From these 24 characteristics, 15 were retained in the model with stepwise selection and subsequently used to generate propensity scores. The selection process used a P value cutoff of 0.05 for a characteristic to enter and remain in the model. In order of stepwise selection, the matching variables were as follows: age group, total enrollment (in months), rhythm medication use, warfarin use, heart failure, sex, chronic obstructive pulmonary disease, number of office visits, coronary artery disease, hypertension, cardiomyopathy, stroke or TIA, number of emergency department visits, diabetes, and region of country.
Based on their propensity for having a cardiac catheter ablation procedure, ablation and nonablation patients were matched on a 1:1 basis with a 4-digit nearest neighbor algorithm. 23 Because of the statistical precision of this matching process, most ablation patients could not be successfully paired with nonablation control subjects.
Outcomes
The primary outcomes of interest were time to event for stroke/TIA diagnoses and heart failure hospitalization. In addition, rates of medication use, based on filled prescriptions, were also assessed as a measure of treatment patterns over time. The stroke/TIA end point was based on a list of ICD-9 diagnosis codes for various types of hemorrhagic and ischemic strokes, as well as TIAs (online-only Data Supplement). Heart failure events were defined as inpatient hospital admissions for which the primary ICD-9 code was a heart failure diagnosis. In addition, to assess for potential "healthy user effect,"
we examined the outcome of hospital admission for pneumonia, on the rationale that an unexpected difference in the rate of pneumonia between groups might indicate an imbalance in the overall health risk of the study groups unaccounted for by propensity matching.
Medication Use
Three categories of medication were of interest with respect to the treatment of AF. These included rate control medications (␤blockers, nondihydropyridine calcium channel blockers, and digoxin), antiarrhythmic drugs, and warfarin. Indicator variables were created for each combination of medication category and 6-month period, and use was defined as one or more prescription fills during the period of interest.
Statistical Analyses

Unadjusted Statistics
Unadjusted comparisons of patient characteristics between treatment arms were performed with 2-sample t-tests for continuous variables and 2 tests for categorical variables. These comparisons were made for all demographics, use measures, comorbidities, and medication use variables. Patient characteristics were first compared among the entire groups of patients meeting inclusion or exclusion criteria. They were then compared among the propensity-matched subsample, to ensure that the matching process resulted in well-balanced groups.
Unadjusted comparisons of event rates for the primary outcomes of time to stroke/TIA or heart failure hospitalization for the propensity-matched ablation and nonablation groups were made using the Kaplan-Meier method and compared between groups with the log-rank test. Annualized event rates for stroke/TIA and heart failure hospitalization were also calculated by dividing total numbers of first events by total number of person-years of follow-up for each group.
Multivariable Models
Multivariable regression analysis was used to model the stroke/TIA and heart failure event data, based on the Cox proportional hazards model. Regressions were performed on the propensity-matched populations, and 3 different models were evaluated for each end point. These models adjusted the relationship between the covariate of interest (ablation versus no ablation) and the respective outcome for factors known to be associated with those outcomes (eg, stroke risk factors), a previously documented history of the condition, and variables found not to be well balanced by the propensity matching. Variables chosen for inclusion in all of these models included treatment arm, a record of a diagnosis code for the event being modeled (stroke/TIA or heart failure) in the 6 months before the analytic start time, age category (Ͻ65 and Ն65 years), and propensity score. In addition, 1 model for each end point added any variable showing a statistically significant difference between treatment arms (PϽ0.05) and another added any variables with near-significant differences (PϽ0.10).
All data analyses for this article were performed with SAS software, version 9.2, of the SAS System for Windows (SAS Institute Inc., Cary, NC).
Results
Study Sample
The structure of our coding algorithm and resultant numbers of identified study subjects are shown in Figure 1A for the ablation cohort and Figure 1B for the antiarrhythmic drug cohort. After applying our full set of inclusion and exclusion criteria, we identified a total of 3194 catheter ablation patients and 6028 antiarrhythmic drug-only patients from the Mar-ketScan database. From this sample, the propensity-matching algorithm produced 801 pairs of patients with similar propensity for having an ablation based on the available and relevant demographics, use, comorbidities, and medication data. In the propensity-matched subsample, the average duration of "follow-up" beyond the analytic start time was 27 months.
Patient characteristics are summarized for both the entire population of patients who met the selection criteria and for the final propensity-matched sample in Table 1 , by cohort (ablation versus nonablation). Several differences were observed between the ablation and nonablation cohorts before matching. Specifically, the ablation patients more often fell into younger age groups, were more often male, and in the 6 months before the analytic start time were less likely to have medical encounters coding for the presence of heart disease (hypertension, ischemic heart disease, or heart failure) or noncardiac comorbid conditions (diabetes, chronic obstructive pulmonary disease, or stroke/TIA). After matching, the patient characteristics appeared well balanced between groups, with the only statistically significant difference between them being the duration of continuous enrollment in their health plan (48 versus 49 months; Pϭ0.009). Figure 2 shows patterns of rate medication, antiarrhythmic medication, and warfarin use in the propensity-matched sample based on whether a prescription was filled within each 6-month interval, up to 36 months. Uses of rate control medications and warfarin were nearly identical between the cohorts over the entire timeframe, with the exception of the time period from day 8 to 6 months, during which rate control drugs and warfarin were used more often in the ablation patients (Pϭ0.019 and PϽ0.001, respectively). In contrast, the use of antiarrhythmic medications decreased more over time in the ablation cohort than in the nonablation cohort (PϽ0.001 for each time period beyond baseline).
Medication Use, Stroke/TIA, and Heart Failure Hospitalization
Kaplan-Meier survival plots showing time to first stroke/ TIA and time to first heart failure hospitalization in the propensity-matched groups are shown in Figure 3 and Figure  4 . The overall rate of stroke/TIA up to 3 years was 3.4% per year in the ablation cohort versus 5.5% in the nonablation cohort, and the 3-year Kaplan-Meier estimates were 8.3% versus 14.1%, respectively (log-rank Pϭ0.005). The unadjusted hazard ratio for stroke/TIA in the propensity-matched ablation versus nonablation cohorts was 0.62 (95% CI, 0.44 -0.86; Pϭ0.005). As shown in Table 2 , the overall rates of TIA and ischemic stroke were higher than the rate of hemorrhagic stroke. In the propensity-matched sample, TIA, ischemic stroke, and hemorrhagic stroke events were all significantly less common in the ablation group compared with the nonablation group.
The rate of new (first) heart failure hospitalization up to 3 years was 1.5% per year in the ablation cohort and 2.2% per year in the nonablation cohort, and the 3-year Kaplan-Meier estimates were 4.5% and 5.5%, respectively (log-rank Pϭ0.155). The Cox regression hazard ratio for heart failure hospitalization in the ablation versus nonablation cohorts, unadjusted for additional predictors, was 0.69 (95% CI, 0.42-1.15; Pϭ0.158).
In the propensity-matched sample, the rate of hospitalization for pneumonia was slightly higher in the ablation cohort than in the nonablation cohort, but this difference was not statistically significant (Table 2 ).
Multivariable Models
Multivariable Cox proportional hazard regression analyses of the time to first stroke/TIA or heart failure event were performed on the 801 propensity-matched pairs to further adjust for potential imbalances between the groups. For each of these end points, 3 models were evaluated and the results are shown in Table 3 and Table 4 . Model 1 for each end point included treatment arm, history of the event being modeled, age category (Ͻ65 and Ն65years), and propensity score as independent variables. Model 2 then added total continuous enrollment, in months, as an additional variable because of the statistically significant difference in this variable between the ablation and nonablation cohorts after propensity matching. Finally, model 3 added diabetes and rate medication use variables because of their borderline significance in difference between cohorts (Pϭ0.062 and Pϭ0.086, respectively) and the known association between diabetes and stroke.
The stroke/TIA regression models all showed statistically significant differences in the rates of events between cohorts, with lower event rates in the ablation cohort. The hazard ratio was negligibly affected by adjustment for the variables in these models, ranging from 0.60 to 0.61, with ablation remaining statistically significant (adjusted PϽ0.005) in each model. Similarly, the trend toward less frequent heart failure hospitalizations in the ablation cohort compared with the nonablation cohort was minimally altered by adjustment for additional variables in the Cox models ( Table 4 ). The hazard ratios ranged from 0.61 to 0.64, with P values from 0.059 to 0.087.
Discussion
In this analysis of a large multistate claims database, we found that a group of 801 selected patients with AF, treated with catheter ablation, had a significantly lower rate of stroke or TIA in the subsequent 3-year period than a propensitymatched group of patients with AF, initially managed with antiarrhythmic drugs and no ablation. The difference in risk was moderately large (hazard ratio, Ϸ0.60 -0.61) and did not appear likely to have been related to anticoagulation practices, which were similar between the groups over time. We did not find a significant difference between propensitymatched groups in the rate of heart failure hospitalization, which occurred less frequently in both groups than stroke/TIA. The risk of stroke in patients with AF is strongly influenced by several demographic and clinical factors, including age, sex, diabetes, hypertension, heart failure, vascular disease, and prior stroke or TIA, and these risk factors inform current anticoagulation strategies for patients with AF. 10 Although it has long been hypothesized that effective suppression of AF itself might lower stroke risk, this concept has proved difficult to verify.
Stroke and TIA are known, but uncommon, risks of AF ablation; the incidence of each has been estimated at Ͻ0.5%. 24 Although randomized trials comparing AF ablation with drug therapy have reported stroke rates, these trials have been small, enrolled mostly healthy patients at expert centers, and involved a limited follow-up duration. Thus, stroke rates have been Ͻ1% in these studies, regardless of treatment approach. 12 A few previous nonrandomized studies have suggested that AF ablation may reduce the risk of stroke. Pappone et al 19 reported a Ͼ50% reduction in "morbid events" (mainly heart failure and ischemic stroke) over a median follow-up of 900 days when comparing a cohort of 589 AF ablation patients from a single center with 582 contemporaneous control patients who elected not to be treated with ablation. 19 However these groups were nonrandomized, the results were not adjusted for potential confounders, and anticoagulation practices over time were not reported. More recently, Bunch et al 25 reported a risk of stroke among patients with AF treated in the Intermountain Health system, almost twice as high at 3 years (multivariable odds ratio, 1.9) in nonablation, compared with ablation, patients. The patients in that study were matched only by age and sex.
Our study extends prior analyses in several ways. First, the study sample is derived from nationally representative groups of patients and health plans and, therefore, may be more generalizable than data from a single center or single state. Second, we tried to minimize or avoid confounding in our analysis. Our propensity-matching method, while sacrificing sample size, resulted in study samples that appeared as similar as possible, at least on measured characteristics. Nevertheless, we took the additional step of adjusting our results using Cox proportional hazards models and found that this made no meaningful difference on our primary results.
Although studies in patients with AF who had preexisting heart failure have suggested that ablation can improve chamber dimensions, ejection fraction, symptoms, and functional capacity, 17, 18 it is unknown whether ablation can alter the risk of heart failure events in the population of patients typically managed with ablation in current practice. Only Ϸ16% of the patients in our propensity-matched sample had a history of heart failure, according to their previous medical claims, and overall the rate of heart failure hospitalization was low. We used a fairly strict definition for heart failure events (ie, hospital admission with heart failure as the principal diagnosis) but believe that the definition was appropriate in the context of this claims-based analysis because alternative definitions (eg, outpatient visits for heart failure or admissions with heart failure as a secondary diagnosis) might have reflected previous diagnoses rather than new events. Our data do not suggest a large difference in heart failure admission rates in this population.
Our analysis has several limitations. First and most important, neither propensity matching nor any other method other than randomization can eliminate bias from unmeasured confounders. Although we adjusted our analysis for the major established risk factors for stroke, in an observational setting, the selection of patients for ablation procedures was nonrandom and unmeasured differences between our propensitymatched groups could account for our findings. Given these limitations, our results cannot be viewed as definitive and do not provide sufficient evidence to fundamentally alter clinical practice or guideline recommendations.
The critical question of whether AF ablation alters the long-term risk of stroke must be answered by randomized trials. Our results reinforce the hypothesis behind studies like the CABANA (Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation) trial, which will provide more definitive evidence, albeit not for a few more years.
This study relied on medical claims data for the identification of patients and for the compilation of their comorbidities and outcomes. Because there is no specific billing code for AF ablation, even the step of identifying AF ablation patients was somewhat uncertain. To address this issue, we developed a detailed coding algorithm using all available information to exclude other procedures (eg, atrioventricular 
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junction ablation) that might be mistakenly classified as AF ablations. It is also possible, because of coding errors or incomplete sampling, that the comorbidities and outcomes we derived from the claims data were inaccurate some of the time. The outcome of stroke/TIA in a claims-based analysis is nowhere near as rigorous as in a clinical trial, in which definitions are standardized and events are adjudicated. However, because we applied consistent coding definitions for the outcomes in both groups, there is no particular reason to believe that inaccuracies in the claims data would introduce bias in any particular direction. Analyses based on claims data also lack clinical detail. We were unable to identify, for example, the subtype of AF or ascertain important measured data, such as serum creatinine level or ejection fraction. Additional information of interest, such as stroke severity or heart rhythm at a hospital admission, cannot be ascertained from our data sources. The claims data we examined do not permit ascertainment of the antiarrhythmic efficacy of either the ablations or drugs.
At present, the main justification for pursuing rhythm control interventions of any kind is the relief of symptoms and improvement in quality of life. Despite the limitations of our approach, our analysis suggests that a wide range of patients treated with catheter ablation for AF between 2005 and 2008 may have experienced better outcomes than similar patients managed initially with antiarrhythmic medications and not ablation. We eagerly await verification or refutation of these findings based on randomized clinical trial evidence.
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